Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
THYROGEN (thyrotropin alfa) is a recombinant human thyroid-stimulating hormone (TSH) administered by injection to stimulate thyroid hormone production and uptake. It is used primarily in thyroid cancer patients undergoing radioactive iodine therapy and diagnostic imaging without requiring thyroid hormone withdrawal. The drug works by binding to TSH receptors on thyroid cells, mimicking the body's natural pituitary hormone.
With LOE approaching and limited Part D volume ($398K, 98 claims in 2023), this product faces significant revenue headwinds and may see contraction in brand team size and investment.
Thyroid Stimulating Hormone
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone
Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration
Worked on THYROGEN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on THYROGEN offers exposure to specialty pharma, rare disease commercialization, and thyroid cancer treatment pathways within a stable, established product. However, the approaching LOE and limited clinical pipeline suggest this role is better suited for professionals seeking operational expertise in mature product management rather than growth-oriented career trajectories.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo